Radiotherapy for stage II testicular seminoma

Gunar K. Zagars, Alan Pollack

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Purpose: To compare the outcome of patients with Stage II seminoma treated with prophylactic mediastinal irradiation, without any supradiaphragmatic irradiation, and with prophylactic left supraclavicular irradiation (PLSCI). Methods and Materials: Between 1960 and 1999, 73 men with Stage II seminoma received postorchiectomy radiotherapy. Before 1984, 36 received prophylactic mediastinal irradiation (Series I); between 1984 and 1992, 17 received no supradiaphragmatic irradiation (Series II); and after 1992, 20 received PLSCI (Series III). The outcomes in these series were compared. Results: The abdominal tumor sizes were as follows: Series I, ≤2 cm, n=4; >2 and ≤5 cm, n=12; >5 and ≤10 cm, n=16; Series II, ≤2 cm, n=1; >2 and ≤5 cm, n=12; >5 and ≤10 cm, n=4; and Series III, ≤2 cm, n=1; >2 and ≤5 cm, n=14; >5 and ≤10 cm, n=5 (p=0.75). The median duration of follow-up was 14.4, 9.3, and 4.5 years for Series I, II, and III, respectively. The 6-year freedom from relapse was 94%, 71%, and 95% for Series I, II, and III, respectively. The differences between Series I and II (p=0.014) and between II and III (p=0.042) were significant. Three patients in Series II had a relapse in their left supraclavicular fossa - a failure pattern abrogated by PLSCI. Conclusions: PLSCI significantly diminishes the likelihood of relapse for Stage IIA, IIB, and IIC seminoma (mass ≤10 cm).

Original languageEnglish (US)
Pages (from-to)643-649
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume51
Issue number3
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Keywords

  • Abdominal metastasis
  • Prophylactic radiation
  • Radiotherapy
  • Seminoma
  • Stage II

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Radiotherapy for stage II testicular seminoma'. Together they form a unique fingerprint.

  • Cite this